日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Insulin glargine 300 U/mL safety data in pregnancy

妊娠期胰岛素甘精300 U/mL安全性数据

Westerbacka, Jukka; Duverne, Marielle; Grulovic, Natasa; Thummisetti, Sreenivas; Doder, Zoran

Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study

在开始使用甘精胰岛素 300 U/mL 后,2 型糖尿病初治患者的治疗满意度得到具有临床意义的改善:一项基于真实世界 ATOS 研究的事后分析

Snoek, Frank; Galstyan, Gagik; Khan, Niaz; Tirosh, Amir; Kesavadev, Jothydev; Vargas-Uricoechea, Hernando; Baghous, Houssem; Mabunay, Maria Aileen; Grulovic, Natasa; Corp Dit Genti, Valerie; Msihid, Jerome; Harris, Stewart

Prevalence and predictors of diabetes-related distress in adults with type 1 diabetes

1 型糖尿病成人患者糖尿病相关困扰的患病率和预测因素

Grulovic, Natasa; Rojnic Kuzman, Martina; Baretic, Maja

Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries

2型糖尿病患者从预混胰岛素方案转换为甘精胰岛素方案:一项来自亚得里亚海国家的前瞻性观察研究

Petrovski, Goran; Gjergji, Dashamir; Grbic, Aleksandra; Vukovic, Blazenko; Krajnc, Mitja; Grulovic, Natasa